Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC.
immune checkpoint inhibitors
obesity
obesity paradox
renal cell carcinoma
tyrosine kinase inhibitors
Journal
Endocrine-related cancer
ISSN: 1479-6821
Titre abrégé: Endocr Relat Cancer
Pays: England
ID NLM: 9436481
Informations de publication
Date de publication:
02 06 2021
02 06 2021
Historique:
received:
22
04
2021
accepted:
05
05
2021
pubmed:
6
5
2021
medline:
15
4
2022
entrez:
5
5
2021
Statut:
epublish
Résumé
Obesity represents a well-known risk factor for renal cell carcinoma development. Several studies evaluated the relationship between obesity and outcome in patients with non-metastatic and metastatic renal cell carcinoma using different parameters such as BMI, visceral fat area and s.c. fat area. These studies suggest that obesity is associated with a better prognosis in renal cell carcinoma patients. This phenomenon is called obesity paradox and it was found in other diseases in which obesity represents an established risk factor such as heart failure, diabetes, atrial fibrillation, hypertension and coronary heart disease. The purpose of this review is to analyze the mechanisms by which obesity increases the risk of renal cell carcinoma development, to describe the evidence available to date about the link obesity-outcome and to evaluate the mechanisms to explain this apparently paradoxical relationship.
Identifiants
pubmed: 33949971
doi: 10.1530/ERC-20-0457
pii: ERC-20-0457
doi:
pii:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM